Integrates genomic data, clinical history, treatment insights, and real-world evidence into one unified workspace, enabling faster, sharper, and consensus-driven MTB decision making.

Enhances trial feasibility, patient stratification, and site selection using real-world cohorts and AI-driven digital twin modeling to improve recruitment and trial outcomes.

Utilizes diverse, multi-modal real-world datasets to accelerate biomarker discovery, validate therapeutic hypotheses, and generate evidence that supports regulatory and scientific advancement.

High-sensitivity circulating tumor DNA testing that detects actionable mutations, tracks treatment response, and overcomes tissue limitations through real-time, non-invasive genomic assessment.

A combined tissue–liquid–germline approach that overcomes tumor heterogeneity, confirms true somatic variants, and delivers the most complete and clinically confident genomic picture for each patient.

A scar-based HRD assay that measures genomic instability to identify HRD-positive tumors more accurately than BRCA-only testing, enabling confident Parp inhibitor therapy selection.

Accurate hereditary cancer testing that identifies inherited risk variants, informs treatment sensitivity such as PARP inhibitor eligibility, and supports family counseling and preventive care.